{"product_id":"targeting-liver-metastases-with-precision-a-patients-guide-to-stereotactic-radiotherapy-srt","title":"Targeting Liver Metastases with Precision: A Patient's Guide to Stereotactic Radiotherapy (SRT)","description":"\u003cp\u003eLiver metastases are a common and serious challenge for patients with colorectal, lung, and breast cancer. Stereotactic radiotherapy (SRT) is a highly precise radiation technique that delivers powerful, focused doses of radiation to liver tumors while protecting surrounding healthy tissue. This review article explains how doctors select patients for SRT, plan the treatment using advanced imaging, choose appropriate doses, and what outcomes and side effects patients can expect. Clinical studies show that local control rates range from 60% to 100% at 1–2 years after SRT, with mostly mild toxicity, making this an increasingly valuable option for patients with a limited number of liver metastases (oligometastases).\u003c\/p\u003e\n\n\u003ch1\u003eTargeting Liver Metastases with Precision: A Patient's Guide to Stereotactic Radiotherapy (SRT)\u003c\/h1\u003e\n\n\u003ch2\u003eTable of Contents\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\u003ca href=\"#ddn-key-points\"\u003eKey Points\u003c\/a\u003e\u003c\/li\u003e\n\n  \u003cli\u003e\u003ca href=\"#background\"\u003eWhy This Research Matters\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#epidemiology\"\u003eHow Common Are Liver Metastases?\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#candidates\"\u003eWho Is a Good Candidate for SRT?\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#planning\"\u003eHow SRT Is Planned: Imaging and Motion Management\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#doses\"\u003eDoses and Fractionation: Finding the Right Recipe\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#outcomes\"\u003eHow Well Does SRT Work? Results from Clinical Studies\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#toxicity\"\u003eSide Effects and Safety\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#conclusions\"\u003eConclusions and Practical Takeaways\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#ddn-faq\"\u003eFrequently Asked Questions\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#source\"\u003eSource Information\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003c!-- ddn:keypoints:start --\u003e\n\u003ch2 id=\"ddn-key-points\"\u003eKey Points\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003eSRT delivers precise, high-dose radiation to liver metastases while sparing healthy tissue, with local control rates of 60–100% at 1–2 years across studies.\u003c\/li\u003e\n\u003cli\u003eGood candidates generally have fewer than three lesions, each under 6 cm, combined under 15 cm, with adequate liver function and reserve.\u003c\/li\u003e\n\u003cli\u003eTreatment planning uses contrast MRI and\/or PET-CT, a triphasic CT, and 4D-CT to account for breathing motion and outline organs at risk.\u003c\/li\u003e\n\u003cli\u003eDoses are not standardized; schedules with BED over 100 Gy are commonly recommended, tailored to lesion size, location, and tumor radiosensitivity.\u003c\/li\u003e\n\u003cli\u003eSevere side effects are uncommon; radiation-induced liver disease has never been reported after liver SRT, and late toxicity remains mild even with long-term follow-up.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c!-- ddn:keypoints:end --\u003e\n\n\n\u003ch2 id=\"background\"\u003eWhy This Research Matters\u003c\/h2\u003e\n\u003cp\u003eThe liver is a common destination for cancer cells that break away from a primary tumor. For many years, radiation therapy to the liver was considered too risky. The healthy liver tissue is highly sensitive to radiation, and nearby organs such as the stomach, duodenum, and right kidney could be easily damaged. As a result, doctors could only offer palliative (pain-relieving) doses of radiation rather than treatments aimed at curing or controlling the disease.\u003c\/p\u003e\n\u003cp\u003eThat has changed dramatically. Stereotactic radiotherapy (SRT), also called stereotactic body radiotherapy (SBRT), uses advanced imaging and precise targeting technology to deliver very high doses of radiation directly to the tumor while keeping the dose to healthy tissue low. This approach helps prevent severe complications like radiation-induced liver disease (RILD), a potentially dangerous condition that damages liver function.\u003c\/p\u003e\n\u003cp\u003eAn emerging concept called the \"metastatic cascade\" helps explain why SRT matters. Research has shown that metastases can spread from the original primary tumor (a linear progression model) or, in some cases, metastases themselves can spawn further metastases (a parallel progression model). By treating a limited number of \"progenitor\" metastases with SRT, doctors may be able to prevent a full-blown \"polymetastatic wave\" — potentially extending survival. This review, authored by a team of Italian radiation oncologists, summarizes the current evidence for SRT in liver oligometastases, focusing on patient selection, treatment planning, dosing, outcomes, and safety.\u003c\/p\u003e\n\n\u003ch2 id=\"epidemiology\"\u003eHow Common Are Liver Metastases?\u003c\/h2\u003e\n\u003cp\u003eLiver metastases are remarkably common. The liver is the \u003cstrong\u003efirst metastatic site in 15–25% of colorectal cancer patients\u003c\/strong\u003e [1, 2]. Autopsy findings show that in 40% of cases, metastases are found \u003cem\u003eonly\u003c\/em\u003e in the liver (confined to the parenchyma, the liver's functional tissue) [3]. In 10–20% of cases, liver metastases appear synchronously — meaning they are present at the same time as the primary tumor is diagnosed [4].\u003c\/p\u003e\n\u003cp\u003eOne population study of \u003cstrong\u003e3,655 patients with colorectal cancer\u003c\/strong\u003e uncovered some important patterns:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003ePatients under 55 years old had a higher incidence of liver metastases (19.8%)\u003c\/li\u003e\n  \u003cli\u003eMales were more affected than females (15.9%)\u003c\/li\u003e\n  \u003cli\u003ePatients with colon cancer (as opposed to rectal cancer) had a higher rate (14.8%)\u003c\/li\u003e\n  \u003cli\u003eCumulative incidences of liver metastases at 1, 2, and 3 years were \u003cstrong\u003e4.3%, 12%, and 16.5%\u003c\/strong\u003e, respectively [5]\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThe liver is also one of the first metastatic sites for lung and breast cancer. In a study of \u003cstrong\u003e912 breast cancer patients\u003c\/strong\u003e, Hoe et al. [6] found a \u003cstrong\u003e5.2% risk\u003c\/strong\u003e of developing liver metastases. Liver metastases are less common for tumors of the bladder, esophagus, head and neck, and pancreas, as well as for rare cancers such as neuroendocrine tumors and ovarian adenocarcinomas [3].\u003c\/p\u003e\n\u003cp\u003eThe characteristics of metastatic disease significantly affect survival. For colorectal cancer patients, the following features were associated with a \u003cstrong\u003e5-year overall survival above 60%\u003c\/strong\u003e:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eSurgical resection of a single metastasis smaller than 5 cm in diameter\u003c\/li\u003e\n  \u003cli\u003eMetastases that appeared at least one year after the primary tumor diagnosis\u003c\/li\u003e\n  \u003cli\u003eLow CEA (carcinoembryonic antigen) levels (a tumor marker)\u003c\/li\u003e\n  \u003cli\u003eNegative surgical margins (no cancer cells at the edge of the removed tissue)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eWhen these favorable features were \u003cem\u003eabsent\u003c\/em\u003e, the 5-year survival dropped to just \u003cstrong\u003e14%\u003c\/strong\u003e [7, 8].\u003c\/p\u003e\n\u003cp\u003eFor breast cancer patients, the data are less encouraging. At five years, median survival after radical (complete) resection of liver metastases from breast cancer ranged from \u003cstrong\u003e18% to 61%\u003c\/strong\u003e — likely due to metastatic spread to other organs and variable responses to systemic therapies. However, an analysis of the National Cancer Database found that, compared with no metastasectomy (surgical removal of metastases), \u003cstrong\u003ehepatic metastasectomy was independently associated with a 37% reduction in the risk of death\u003c\/strong\u003e (hazard ratio [HR]: 0.63; confidence interval [CI]: 0.44–0.91; p = 0.01) in selected subgroups of patients [9]. This means that for properly chosen patients, aggressively treating liver metastases can meaningfully improve survival.\u003c\/p\u003e\n\n\u003ch2 id=\"candidates\"\u003eWho Is a Good Candidate for SRT?\u003c\/h2\u003e\n\u003cp\u003eSelecting the right patients for SRT is crucial. Doctors consider several factors carefully before recommending treatment. Accurate assessment of the extent of liver disease is the first step [4, 13].\u003c\/p\u003e\n\n\u003ch3\u003eImaging: How Liver Metastases Are Detected\u003c\/h3\u003e\n\u003cp\u003e\u003cstrong\u003eConventional ultrasound\u003c\/strong\u003e is often the first test because it is non-invasive, safe, and reproducible. However, its sensitivity in detecting liver metastases ranges from \u003cstrong\u003e53% to 84%\u003c\/strong\u003e — and drops to just \u003cstrong\u003e20%\u003c\/strong\u003e when metastases are smaller than 1 cm in diameter [14]. The addition of \u003cstrong\u003eecho-color-Doppler\u003c\/strong\u003e, which detects and characterizes blood flow, along with \u003cstrong\u003eharmonic imaging\u003c\/strong\u003e, improves diagnostic accuracy [15]. These techniques improve the signal-to-noise ratio, reduce image artifacts, and allow real-time, full dynamic contrast enhancement of suspicious lesions.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eComputed tomography (CT)\u003c\/strong\u003e with contrast medium is the standard procedure for evaluating liver lesions, because it is fast and less affected by motion artifacts. The venous phase of the CT scan typically identifies liver metastases best, while the arterial phase detects hypervascularized (high blood-flow) tumors such as neuroendocrine carcinoma, melanoma, and clear cell renal carcinoma [17].\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eMagnetic resonance imaging (MRI)\u003c\/strong\u003e has superior soft-tissue contrast compared with CT, allowing it to better characterize small lesions — especially in a fatty (steatotic) liver — and to better differentiate small cysts from solid lesions [18]. That said, data on MRI sensitivity and specificity are often inconsistent and depend on the type of contrast agent used [19].\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePositron emission tomography (PET-CT)\u003c\/strong\u003e using fluorodeoxyglucose (FDG) has a wide range of reported sensitivity (54–100%) and specificity (58–100%) [20], depending on primary tumor type, metastasis location, and size. Because MRI and CT remain the standard of care — they are widely available and cost-effective — PET-CT plays a complementary role in liver metastasis diagnosis, although it is valuable for identifying metastases outside the liver (extrahepatic disease) [21].\u003c\/p\u003e\n\n\u003ch3\u003eKey Selection Criteria for SRT\u003c\/h3\u003e\n\u003cp\u003eWhen deciding whether SRT is appropriate, doctors evaluate the following:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eNumber of lesions:\u003c\/strong\u003e Fewer than 3 metastatic lesions is generally suggested.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSize of lesions:\u003c\/strong\u003e Preferably each lesion should be smaller than 6 cm, and the combined total should be under 15 cm.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eLiver function:\u003c\/strong\u003e Pre-existing liver impairment — such as hyperbilirubinemia (high bilirubin levels) over 3, or Child-Pugh class 2 or 3 cirrhosis — reduces healthy tissue tolerance to radiation [22].\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eHepatic reserve:\u003c\/strong\u003e Ideally, the total liver volume should be more than 1,000 mL, with at least 700 mL of the liver spared from radiation doses above 15 Gy [23].\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eClinical factors also matter. Age under 60 years, good performance status (ability to carry out daily activities), absence of comorbidities, and favorable primary tumor histology (such as colorectal and breast tumors) are all associated with better outcomes after ablative therapy [10, 11, 24, 25].\u003c\/p\u003e\n\n\u003ch2 id=\"planning\"\u003eHow SRT Is Planned: Imaging and Motion Management\u003c\/h2\u003e\n\u003cp\u003ePlanning for liver SRT is a carefully orchestrated process that begins long before the actual treatment. Because the liver sits deep inside the body and moves with breathing, doctors must address two major challenges: \u003cstrong\u003eprecisely identifying the tumor\u003c\/strong\u003e and \u003cstrong\u003emanaging respiratory motion\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ch3\u003eTarget Contouring\u003c\/h3\u003e\n\u003cp\u003eInformation from contrast MRI and\/or PET-CT is crucial for contouring — the process of outlining the exact boundaries of the tumor on imaging [26, 27]. These imaging techniques best visualize the true extent of metastatic disease within the liver tissue. A \u003cstrong\u003etriphasic CT scan\u003c\/strong\u003e (acquiring images during arterial, venous, and time-delayed phases after contrast injection) is the first step in treatment planning, because liver metastases can behave differently during each phase of contrast perfusion.\u003c\/p\u003e\n\n\u003ch3\u003eManaging Liver Motion\u003c\/h3\u003e\n\u003cp\u003eThe liver moves with every breath and is also affected by bowel filling. To deliver high-dose radiation safely, doctors use motion management strategies:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFour-dimensional CT (4D-CT)\u003c\/strong\u003e: This imaging technique captures the tumor's position throughout the entire breathing cycle, creating a map of its movement.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAbdominal compression\u003c\/strong\u003e: A device presses on the abdomen to limit diaphragm movement and reduce respiratory motion during both planning CT and treatment delivery.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eBreath-hold techniques\u003c\/strong\u003e: Patients hold their breath at specific points during treatment to momentarily \"freeze\" the tumor in place.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTarget tracking systems\u003c\/strong\u003e: Advanced systems recognize internal fiducial markers (tiny implants placed in or near the tumor) and track their respiratory movements in real time [28].\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eDuring contouring, doctors create an \u003cstrong\u003einternal target volume (ITV)\u003c\/strong\u003e that includes the tumor volume plus its small respiratory range of motion. Margins around the target are then added based on the contouring method, respiratory management technique, and how precisely the patient can be repositioned for each treatment session [29].\u003c\/p\u003e\n\u003cp\u003eIn addition to the liver, doctors also outline all \u003cstrong\u003eorgans at risk (OARs)\u003c\/strong\u003e — the right and left kidneys, duodenum, bowel, esophagus, heart, and spinal cord — to ensure these structures receive as little radiation as possible.\u003c\/p\u003e\n\n\u003ch3\u003eTreatment Delivery Technology\u003c\/h3\u003e\n\u003cp\u003eLiver SRT is typically delivered using modern linear accelerators equipped with image-guided radiation therapy (IGRT) systems. \u003cstrong\u003eFiducial markers\u003c\/strong\u003e (tiny gold seeds implanted near the tumor) serve as target surrogates, allowing precise daily repositioning of the patient and on-line assessment of target position [45, 46]. This is important because standard X-ray images during treatment have poorer resolution than diagnostic scans.\u003c\/p\u003e\n\u003cp\u003eSome patients may be treated on dedicated therapy units such as \u003cstrong\u003eCyberKnife\u003c\/strong\u003e, a robotic system that tracks the tumor and delivers radiation from many different angles. More recently, \u003cstrong\u003eMRI-guided adaptive radiotherapy\u003c\/strong\u003e — which allows real-time MRI imaging before and continuously during treatment — has been used for liver metastases. This technology offers clear advantages:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eImproved soft-tissue visualization of the target and organs at risk\u003c\/li\u003e\n  \u003cli\u003eFiner tracking, which allows smaller treatment margins\u003c\/li\u003e\n  \u003cli\u003eMinimization or elimination of external surrogates (like skin marks)\u003c\/li\u003e\n  \u003cli\u003eNo additional imaging radiation dose to the patient [47–49]\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2 id=\"doses\"\u003eDoses and Fractionation: Finding the Right Recipe\u003c\/h2\u003e\n\u003cp\u003eOne of the most important messages from this review is that \u003cstrong\u003edoses and fractionation schedules for liver SRT have not yet been standardized\u003c\/strong\u003e [30]. \"Fractionation\" refers to how the total radiation dose is divided into smaller sessions (fractions). Despite this lack of uniformity, clear patterns have emerged from the research.\u003c\/p\u003e\n\n\u003ch3\u003eThe Importance of BED\u003c\/h3\u003e\n\u003cp\u003eThe \u003cstrong\u003ebiologically effective dose (BED)\u003c\/strong\u003e is a way of comparing different dose schedules to determine their true biological impact on tumors. The best local control (LC) rates were achieved with \u003cstrong\u003eBED values over 100 Gy\u003c\/strong\u003e [31, 32]. Higher is often better:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eJoo et al. [33]\u003c\/strong\u003e demonstrated that BED values between \u003cstrong\u003e132 and 180 Gy\u003c\/strong\u003e improved outcomes, achieving an 89% local control rate at 3 years.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eChang et al. [34]\u003c\/strong\u003e proposed a dose of at least \u003cstrong\u003e48 Gy in 3 fractions\u003c\/strong\u003e, while respecting the radiation limits of organs at risk.\u003c\/li\u003e\n  \u003cli\u003eFor lesions \u003cstrong\u003esmaller than 3 cm\u003c\/strong\u003e, a total dose of \u003cstrong\u003e60 Gy in 3 fractions\u003c\/strong\u003e was recommended [35].\u003c\/li\u003e\n  \u003cli\u003eFor lesions \u003cstrong\u003elarger than 3 cm\u003c\/strong\u003e, Scorsetti et al. [36] escalated the dose up to \u003cstrong\u003e75 Gy in 3 fractions\u003c\/strong\u003e.\u003c\/li\u003e\n  \u003cli\u003eA phase I dose escalation trial of single-fraction SRT delivered \u003cstrong\u003e35 Gy and 40 Gy\u003c\/strong\u003e to lesions ranging from 0.5 to 5.0 cm (median size 2 cm), while respecting organ-at-risk constraints, such as ensuring at least 700 cc of normal liver received less than 9.1 Gy [37].\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eAn important finding from a large study of \u003cstrong\u003e500 liver and lung metastases in 388 patients\u003c\/strong\u003e treated with SRT (Klement et al.) was that patients who had \u003cstrong\u003enot received prior chemotherapy\u003c\/strong\u003e achieved higher local control rates. The researchers predicted that a \u003cstrong\u003e90% tumor control probability (TCP) at 2 years\u003c\/strong\u003e could be achieved with a BED of \u003cstrong\u003e187 Gy\u003c\/strong\u003e in chemotherapy-naive patients, but that a much higher BED of \u003cstrong\u003e300 Gy\u003c\/strong\u003e would be needed in patients who had received prior chemotherapy [38].\u003c\/p\u003e\n\n\u003ch3\u003ePrimary Tumor Type Matters\u003c\/h3\u003e\n\u003cp\u003eNot all liver metastases respond to radiation equally. The primary tumor's biology influences radiosensitivity — how easily the cancer cells are killed by radiation. Ahmed et al. [39] developed a multigene expression model of tumor radiosensitivity and found that radioresistance (resistance to radiation) was \u003cstrong\u003ehigher in colorectal metastases\u003c\/strong\u003e than in, for example, anal squamous cell cancer, breast cancer, and lung adenocarcinoma. Similarly, Klement et al. [40] showed that \u003cstrong\u003ebreast cancer metastases responded better\u003c\/strong\u003e to SRT than colorectal liver metastases: a 2-year tumor control probability of 90% was achieved with a BED of 157 Gy for breast cancer, versus 257 Gy for colorectal cancer.\u003c\/p\u003e\n\n\u003ch3\u003eHow Doses Are Prescribed\u003c\/h3\u003e\n\u003cp\u003eDose prescriptions vary between centers. The dose is usually prescribed to a \u003cstrong\u003eperipheral reference isodose\u003c\/strong\u003e or to the \u003cstrong\u003eisocenter\u003c\/strong\u003e (the central point of the treatment beams) [41–43]. Prescribing to an isodose means the target dose is specified at the edges of the tumor, which results in a higher dose at the center. For example, a prescription of 36–37.5 Gy in 3 fractions to the 67% peripheral isodose means the isocenter actually receives more than 50 Gy. Regardless of the method, treatment plans must be optimized so that the prescription dose covers \u003cstrong\u003eat least 90% of the planning target volume (PTV)\u003c\/strong\u003e. Coverage below 80% is not considered acceptable.\u003c\/p\u003e\n\u003cp\u003eFor organ-at-risk dose limits, most centers rely on the reference values from \u003cstrong\u003eTask Group 101 (AAPM101)\u003c\/strong\u003e of the American Association of Physicists in Medicine [44].\u003c\/p\u003e\n\n\u003ch2 id=\"outcomes\"\u003eHow Well Does SRT Work? Results from Clinical Studies\u003c\/h2\u003e\n\u003cp\u003eThe evidence base for liver SRT includes both retrospective studies (looking back at patient records) and prospective trials (tracking patients forward in time). While most retrospective studies were limited by short follow-ups and included different primary tumor types — making outcomes difficult to compare directly [52, 53] — the overall picture is encouraging.\u003c\/p\u003e\n\n\u003ch3\u003eLong-Term Local Control\u003c\/h3\u003e\n\u003cp\u003eIn one long-term experience, Scorsetti et al. demonstrated that the \u003cstrong\u003e5-year local control rate was 78%\u003c\/strong\u003e [54]. After single-fraction SRT, the \u003cstrong\u003e4-year actuarial local control rate was 96.6%\u003c\/strong\u003e [37]. Menichelli et al. showed that local control correlated with lesion size, BED value, and primary tumor histology [55]. The use of advanced motion management also improved local control: an analysis involving 623 metastases found a hazard ratio of \u003cstrong\u003e0.46 (95% CI: 0.29–0.72; p ≤ 0.001)\u003c\/strong\u003e, meaning that advanced motion management roughly halved the risk of treatment failure [41].\u003c\/p\u003e\n\n\u003ch3\u003eResults from Retrospective Studies\u003c\/h3\u003e\n\u003cp\u003eThe following studies summarize real-world experience with SRT for liver metastases:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eChang et al. (2011) [34]\u003c\/strong\u003e: 65 patients, 102 lesions, colorectal cancer. Doses of 22–60 Gy in 1–6 fractions. Median follow-up 14.4 months. 1-year local control 62%; 1-year overall survival 72%. Grade ≥ 2 toxicity in 3%.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMenichelli et al. (2012) [55]\u003c\/strong\u003e: 100 patients, 173 lesions, colorectal\/breast\/lung cancers. Median dose 35 Gy. Follow-up 15 months. 1-year local control 78%; 2-year local control 62%. No grade ≥ 3 toxicity.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eWulf et al. (2006) [56]\u003c\/strong\u003e: 44 patients, 51 lesions, colon\/breast\/ovary cancers. 30–37.5 Gy in 3 fractions or 26 Gy in 1 fraction. Follow-up 24 months. 1-year local control 92%; 2-year local control 66%; 1-year overall survival 72%; 2-year overall survival 32%. No grade ≥ 2 toxicity.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eLanciano et al. (2012) [57]\u003c\/strong\u003e: 30 patients, 41 lesions, colorectal\/breast\/other cancers. 36–60 Gy in 3 fractions or 50 Gy in 5 fractions. Follow-up 22 months. 1-year local control 92%; 2-year local control 56%; 1-year overall survival 73%; 2-year overall survival 31%. No grade ≥ 3 toxicity.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eKatz et al. (2007) [65]\u003c\/strong\u003e: 69 patients, 174 lesions, colorectal\/breast\/pancreas\/lung\/other cancers. 30–55 Gy in 5–15 fractions. Follow-up 14.5 months. Local control 46% at 6 months and 57% at 20 months. No grade ≥ 3 toxicity.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eVautravers-Dewas et al. (2011) [66]\u003c\/strong\u003e: 42 patients, 62 lesions. 40 Gy in 4 fractions or 45 Gy in 3 fractions. Follow-up 14.3 months. 2-year local control 86%; 2-year overall survival 48%.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eHabermehl et al. (2013) [67]\u003c\/strong\u003e: 138 patients, 138 lesions, colorectal\/breast\/pancreas\/other cancers. 10 Gy in 1 fraction. Follow-up 21.7 months. 1-year local control 69%; 18-month local control 59%; 1-year overall survival 70%; 18-month overall survival 59%.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eResults from Prospective Trials\u003c\/h3\u003e\n\u003cp\u003eProspective trials confirm the promise of SRT:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eRusthoven et al. (2009) [35]\u003c\/strong\u003e (Phase I\/II): 47 patients, 63 lesions, multiple histologies. 36–60 Gy in 3 fractions. Follow-up 16 months. 1-year local control 95%; 2-year local control 92%; 2-year overall survival 62%. Grade ≥ 3 toxicity in 2%.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eScorsetti et al. (2013) [36]\u003c\/strong\u003e (Phase II): 61 patients, 76 lesions, colorectal\/breast\/other. 75 Gy in 3 fractions. Follow-up 12 months. 1-year local control 83%; 1-year overall survival 64%; 18-month overall survival 65%. Grade 3 toxicity in 2%.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFolkert et al. (2020) [37]\u003c\/strong\u003e (Phase I): 33 patients, 39 lesions, colorectal\/kidney\/other. 35 Gy or 40 Gy in 1 fraction. Follow-up 25.9 months. 2-year local control 82.0%; 4-year local control 49.7%; 4-year overall survival for the entire cohort 96.6%. Grade ≥ 3 toxicity in 0%.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMendez-Romero et al. (2006) [42]\u003c\/strong\u003e (Phase I\/II): 27 patients, 34 lesions, colorectal\/hepatocellular\/other. 30–37.5 Gy in 3 fractions. Follow-up 12.9 months. 1-year local control 100%; 2-year local control 86%; 1-year overall survival 85%; 2-year overall survival 62%. Grade 3 toxicity in 4%.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eHoyer et al. (2006) [62]\u003c\/strong\u003e (Phase II): 64 patients, 44 lesions, colorectal cancer. 45 Gy in 3 fractions. Follow-up 51.6 months. 2-year local control 79%; 2-year overall survival 38%. Grade ≥ 3 toxicity in 4%.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eLee et al. (2009) [64]\u003c\/strong\u003e (Phase I): 68 patients, 140 lesions, colorectal\/breast\/other. 27.7–60 Gy in 6 fractions. Follow-up 10.8 months. 1-year local control 71%; 2-year local control 56%. No toxicity reported.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eRule et al. (2011) [68]\u003c\/strong\u003e (Phase I): 27 patients, 37 lesions, colorectal\/other. 30 Gy in 3 fractions, 50 Gy in 5 fractions, or 60 Gy in 5 fractions. Follow-up 20 months. Local control: 89% with 30 Gy, 89% with 50 Gy, 100% with 60 Gy. Grade ≥ 3 toxicity in 2%.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eEffect on Overall Survival\u003c\/h3\u003e\n\u003cp\u003eThe impact of SRT on overall survival is less clear-cut. Although local control rates remained stable for years after treatment, survival rates were high in the first two years (30–70%) but then tended to decline [56, 57]. One important note: \u003cstrong\u003eout-of-field liver progression\u003c\/strong\u003e — the appearance of new metastases elsewhere in the liver — occurred in \u003cstrong\u003e45% of cases\u003c\/strong\u003e [58].\u003c\/p\u003e\n\u003cp\u003eMetastatic progression in the liver or other organs was related to several factors:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eNumber of lesions:\u003c\/strong\u003e Patients with ≤ 3 metastases had a lower risk of subsequent metastatic spread.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eLesion size:\u003c\/strong\u003e Lesions should be ≤ 5–6 cm in maximum diameter for better outcomes.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eType of primary tumor\u003c\/strong\u003e and \u003cstrong\u003ehistological grading\u003c\/strong\u003e (how aggressive the cancer looks under a microscope).\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSystemic treatments\u003c\/strong\u003e during or after SRT aimed at controlling micrometastases may improve outcomes [10, 24, 41].\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eRandomized trials are still needed to better define patient selection and to determine how to integrate SRT with other local treatments and systemic therapies [59].\u003c\/p\u003e\n\n\u003ch2 id=\"toxicity\"\u003eSide Effects and Safety\u003c\/h2\u003e\n\u003cp\u003eReassuringly, severe side effects from liver SRT are uncommon.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRadiation-induced liver disease (RILD)\u003c\/strong\u003e, characterized by ascites (fluid buildup in the abdomen), hepatosplenomegaly (enlarged liver and spleen), and elevated alkaline phosphatase (a liver enzyme), has \u003cstrong\u003enever been reported\u003c\/strong\u003e as an adverse event following SRT for liver metastases [60].\u003c\/p\u003e\n\u003cp\u003eThe most common side effects are laboratory abnormalities rather than symptoms patients can feel:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eIncreases in liver enzymes [45]\u003c\/li\u003e\n  \u003cli\u003eHyperbilirubinemia (elevated bilirubin levels) [61]\u003c\/li\u003e\n  \u003cli\u003eHypoalbuminemia (low blood albumin, a protein made by the liver) [61]\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eToxicity after SRT is linked to high doses reaching nearby organs, particularly the \u003cstrong\u003eright colic flexure\u003c\/strong\u003e (the bend where the ascending colon meets the transverse colon) and the \u003cstrong\u003egastro-duodenal tract\u003c\/strong\u003e (stomach and first part of the small intestine), because of their proximity to the liver. In one report, among 3 patients who received a total bowel dose of ≥ 30 Gy in 3 fractions, \u003cstrong\u003e2 developed duodenal ulceration and 1 developed colon perforation\u003c\/strong\u003e [29]. This is why careful treatment planning is so important.\u003c\/p\u003e\n\u003cp\u003eWhen the target lesion is located in liver segments IV and V (segments near the gastrointestinal tract), or when previous metastases have been surgically removed, doctors may advise reducing the total prescribed dose or increasing the number of fractions to lower the risk to the bowel [63].\u003c\/p\u003e\n\u003cp\u003eThe \u003cstrong\u003eribs\u003c\/strong\u003e are another organ at risk. Lee et al. [64] diagnosed rib fractures at 6 and 23 months after SRT in 2 patients who had received maximum rib doses of \u003cstrong\u003e51.8 Gy and 66.2 Gy\u003c\/strong\u003e (at 0.5 cm³), respectively.\u003c\/p\u003e\n\u003cp\u003eOverall, late toxicity remains mild even with long-term follow-up. In one study, only \u003cstrong\u003e1 patient experienced late grade 3 toxicity\u003c\/strong\u003e at 6 months (severe chest wall pain), while \u003cstrong\u003e2 patients complained of grade 2 moderate chest wall pain\u003c\/strong\u003e at 5 and 7 months, respectively [36]. Another study reported a single case of liver failure leading to patient death [62], but this is an extremely rare event.\u003c\/p\u003e\n\n\u003ch2 id=\"conclusions\"\u003eConclusions and Practical Takeaways\u003c\/h2\u003e\n\u003cp\u003eSRT is a \u003cstrong\u003evalid and effective treatment option\u003c\/strong\u003e for oligometastatic liver disease. Across studies, local control rates at 1 year ranged from \u003cstrong\u003e66% to 100%\u003c\/strong\u003e, and at 2 years from \u003cstrong\u003e56% to 100%\u003c\/strong\u003e. The treatment is well-tolerated, with mostly mild and manageable side effects.\u003c\/p\u003e\n\u003cp\u003eFor patients considering liver SRT, here are the key practical takeaways:\u003c\/p\u003e\n\u003col\u003e\n  \u003cli\u003eTreatment planning should be based on contrast MRI and\/or PET-CT, with a triphasic CT scan as the first step.\u003c\/li\u003e\n  \u003cli\u003eA 4D-CT scan is required to evaluate and account for tumor motion from breathing.\u003c\/li\u003e\n  \u003cli\u003eDoses and fractionation are not standardized and should be tailored to each patient, based on lesion size, location, and the radiosensitivity of the primary tumor type.\u003c\/li\u003e\n  \u003cli\u003eSchedules with BED values over 100 Gy are commonly recommended for the best local control.\u003c\/li\u003e\n  \u003cli\u003eHigh-dose SRT is effective, safe, and well-tolerated, with a mild late-toxicity profile even in long-term follow-up.\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003cp\u003eIf you are a patient with liver metastases, especially from colorectal or breast cancer, and have a limited number of lesions (oligometastatic disease), SRT may offer a meaningful chance at long-term control. Discuss with your oncology team whether you meet the selection criteria and whether a consultation with a radiation oncologist experienced in liver SRT is appropriate for your situation.\u003c\/p\u003e\n\n\u003c!-- ddn:faq:start --\u003e\n\u003ch2 id=\"ddn-faq\"\u003eFrequently Asked Questions\u003c\/h2\u003e\n\u003ch3\u003eWho is a good candidate for stereotactic radiotherapy (SRT) for liver metastases?\u003c\/h3\u003e\n\u003cp\u003eDoctors generally consider SRT when there are fewer than three metastatic lesions, each preferably smaller than 6 cm and combined under 15 cm. Good liver function matters: pre-existing impairment such as bilirubin over 3 or Child-Pugh class 2 or 3 cirrhosis reduces tolerance. Ideally total liver volume exceeds 1,000 mL with at least 700 mL spared from doses above 15 Gy. Age under 60, good performance status, and favorable tumor types also help.\u003c\/p\u003e\n\u003ch3\u003eHow is SRT planned to account for liver movement during breathing?\u003c\/h3\u003e\n\u003cp\u003eBecause the liver moves with every breath, planning uses motion management. A four-dimensional CT captures the tumor's position throughout the breathing cycle. Abdominal compression limits diaphragm movement, breath-hold techniques briefly freeze the tumor, and target tracking systems follow internal fiducial markers in real time. Doctors then create an internal target volume that includes the tumor plus its respiratory range, and outline organs at risk to keep their radiation dose low.\u003c\/p\u003e\n\u003ch3\u003eWhat side effects can I expect after liver SRT?\u003c\/h3\u003e\n\u003cp\u003eSevere side effects are uncommon. Radiation-induced liver disease has never been reported as an adverse event after SRT for liver metastases. The most common side effects are laboratory abnormalities rather than symptoms: increases in liver enzymes, elevated bilirubin, and low blood albumin. Toxicity is linked to high doses reaching nearby organs such as the bowel and stomach. Late toxicity remains mild even with long-term follow-up, though rare events like rib fracture or bowel injury have been reported.\u003c\/p\u003e\n\u003ch3\u003eWhat does the biologically effective dose (BED) mean for my treatment?\u003c\/h3\u003e\n\u003cp\u003eBED compares different dose schedules to estimate their biological impact on tumors. Higher BED values were associated with better local control. In one analysis, BED over 100 Gy produced the highest local control rates, and BED between 132 and 180 Gy achieved an 89% local control rate at three years. Because doses and fractionation are not standardized, your radiation oncologist tailors the schedule to your lesion size, location, and tumor type.\u003c\/p\u003e\n\u003ch3\u003eHow well does SRT control liver metastases?\u003c\/h3\u003e\n\u003cp\u003eAcross clinical studies, local control rates ranged from 60% to 100% at one to two years after SRT. In one long-term experience, the five-year local control rate was 78%. After single-fraction SRT, the four-year local control rate was 96.6%. Results vary with lesion size, BED value, and primary tumor histology. Advanced motion management roughly halved the risk of treatment failure in an analysis involving 623 metastases.\u003c\/p\u003e\n\u003ch3\u003eDoes SRT improve overall survival for liver metastases?\u003c\/h3\u003e\n\u003cp\u003eThe impact on overall survival is less clear-cut. Survival rates were high in the first two years (30–70%) but then tended to decline, even though local control remained stable. Out-of-field liver progression occurred in 45% of cases. Factors linked to lower risk of subsequent spread include three or fewer metastases, lesions 5–6 cm or smaller, and favorable primary tumor type. Randomized trials are still needed to define how SRT integrates with other treatments.\u003c\/p\u003e\n\u003ch3\u003eWhat imaging is used to detect and plan treatment for liver metastases?\u003c\/h3\u003e\n\u003cp\u003eContrast MRI and\/or PET-CT are crucial for outlining the exact tumor boundaries. A triphasic CT scan, which takes images during arterial, venous, and delayed phases after contrast injection, is the first step in treatment planning because liver metastases can behave differently in each phase. A 4D-CT scan is required to evaluate tumor motion from breathing. These imaging techniques together help doctors target the tumor precisely while sparing healthy liver tissue.\u003c\/p\u003e\n\u003ch3\u003eI have a few liver metastases from colorectal cancer and was offered stereotactic radiotherapy — when should I get a second opinion?\u003c\/h3\u003e\n\u003cp\u003eA second opinion is reasonable when the number, size, or location of your liver metastases sits near the selection thresholds: fewer than 3 lesions, each under 6 cm, combined under 15 cm, with adequate liver reserve. It is also worth confirming whether your primary tumor type and prior chemotherapy affect the dose needed, since breast metastases respond at lower doses than colorectal ones. Because doses and fractionation are not standardized, an independent review of imaging, motion management, and organ-at-risk limits can clarify whether SRT is appropriate. Diagnostic Detectives Network provides independent expert second opinions.\u003c\/p\u003e\n\u003c!-- ddn:faq:end --\u003e\n\n\u003ch2 id=\"source\"\u003eSource Information\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eOriginal article title:\u003c\/strong\u003e Stereotactic radiotherapy for liver oligometastases\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eAuthors:\u003c\/strong\u003e Claudia Menichelli, Franco Casamassima, Cynthia Aristei, Gianluca Ingrosso, Simona Borghesi, Fabio Arcidiacono, Valentina Lancellotta, Ciro Franzese, Stefano Arcangeli\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eJournal:\u003c\/strong\u003e Reports of Practical Oncology and Radiotherapy, 2022, Vol. 27, No. 1, pages 32–39. DOI: 10.5603\/RPOR.a2021.0130\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eAffiliations:\u003c\/strong\u003e Ecomedica Radiotherapy, Empoli, Italy; University of Perugia and Perugia General Hospital, Italy; Radiation Oncology Unit of Arezzo-Valdarno, Italy; S. Maria Hospital, Terni, Italy; Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy; Humanitas Clinical and Research Hospital, Rozzano, Milan, Italy; Policlinico S. Gerardo and University of Milan Bicocca, Milan, Italy.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDisclosures:\u003c\/strong\u003e The authors declared no conflicts of interest. This publication was prepared without any external funding. Ethical approval was not necessary for this review article.\u003c\/p\u003e\n\u003cp\u003eThis patient-friendly article is based on peer-reviewed research. It is intended for educational purposes and does not replace professional medical advice. Always consult your oncology care team about your individual treatment options.\u003c\/p\u003e","brand":"DiagnosticDetectives.Com","offers":[{"title":"Default Title","offer_id":47699384074396,"sku":null,"price":0.0,"currency_code":"USD","in_stock":true}],"url":"https:\/\/diagnosticdetectives.com\/de\/products\/targeting-liver-metastases-with-precision-a-patients-guide-to-stereotactic-radiotherapy-srt","provider":"DiagnosticDetectives.Com","version":"1.0","type":"link"}